Table 2.
Selected demographic and clinical characteristics according to progression-free survival and overall survival among epithelial ovarian cancer patients
| Variables | PFS | OS | ||
|---|---|---|---|---|
| No./Events | HR (95%CI)† | No./Events | HR (95%CI)† | |
| Age at diagnosis | ||||
| ≤ 50 | 266/110 | 1.00 (Ref) | 266/96 | 1.00 (Ref) |
| > 50 | 341/152 | 1.24 (0.96-1.60) | 341/137 | 1.27 (0.97-1.66) |
| Comorbidity | ||||
| No | 336/132 | 1.00 (Ref) | 336/111 | 1.00 (Ref) |
| Yes | 271/130 | 1.42 (1.10-1.82) | 271/122 | 1.58 (1.22-2.59) |
| Performance status | ||||
| 0-1 | 153/62 | 1.00 (Ref) | 153/52 | 1.00 (Ref) |
| 2 | 302/118 | 1.00 (0.72-1.38) | 302/104 | 1.19 (0.84-1.68) |
| ≥3 | 152/82 | 1.27 (0.88-1.83) | 152/77 | 1.35 (0.92-1.98) |
| FIGO stage (%) | ||||
| I-II | 253/52 | 1.00 (Ref) | 253/45 | 1.00 (Ref) |
| III | 313/176 | 2.50 (1.75-3.58) | 313/153 | 2.35 (1.62-3.42) |
| IV | 41/34 | 7.05 (4.42-11.24) | 41/35 | 7.77 (4.80-12.57) |
| Histologic type (%) | ||||
| Serous | 434/214 | 1.00 (Ref) | 434/185 | 1.00 (Ref) |
| Non-serous | 173/48 | 0.79 (0.57-1.11) | 173/48 | 0.98 (0.70-1.38) |
| Residual disease | ||||
| None detectable | 373/113 | 1.00 (Ref) | 373/91 | 1.00 (Ref) |
| ≤ 1 cm | 114/68 | 1.72 (1.24-2.39) | 114/64 | 2.19 (1.56-3.09) |
| > 1 cm | 120/81 | 1.96 (1.42-2.69) | 120/78 | 2.50 (1.79-3.47) |
| Ascites | ||||
| No | 257/132 | 1.00 (Ref) | 257/123 | 1.00 (Ref) |
| Yes | 350/130 | 1.06 (0.81-1.39) | 350/110 | 1.24 (0.93-1.65) |
| Grading | ||||
| Grade 1 | 31/10 | 1.00 (Ref) | 31/8 | 1.00 (Ref) |
| Grade 2 | 163/59 | 1.11 (0.57-2.17) | 163/50 | 1.73 (0.82-3.64) |
| Grade 3 | 413/193 | 1.42 (0.70-2.87) | 413/175 | 2.02 (0.93-4.39) |
CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.
†HRs (95% CIs) for progression-free survival and overall survival were estimated by using multivariable proportional hazard models, mutually adjusted for all other variables listed in the table.